Introduction La leptospirose est une zoonose particulièrement fréquente dans les départements et régions d’Outre-mer (DROM), où son incidence est 20 à 50 fois supérieure à celle observée en France hexagonale. Malgré ce constat, les études prospectives restent rares. Des incertitudes persistent quant à la prise en charge thérapeutique, la pertinence de certains tests diagnostiques, les facteurs pronostiques ou l’identification des populations à risque. Depuis l’inscription de la leptospirose comme maladie à déclaration obligatoire en août 2023, la nécessité d’un dispositif d’observation pérenne et harmonisé à l’ensemble des DROM s’est renforcée. Méthodologie LEPTO-FROG (LEPTOspirosis FRench Overseas Group registry) a pour ambition d’être le premier recueil multicentrique et prospectif consacré à la leptospirose dans les DROM. Ce registre s’appuie sur un réseau déjà structuré, associant cliniciens (infectiologues, réanimateurs, urgentistes) et microbiologistes. Les données épidémiologiques, clinico-biologiques, diagnostiques et thérapeutiques des patients pris en charge à l’hôpital pour une leptospirose confirmée ou probable seront recueillies via un e-CRF standardisé, complémentaire au formulaire de déclaration obligatoire. Chaque DROM dispose d’un binôme d’infectiologues référent qui assure : le lien avec les laboratoires, la vérification de l’exhaustivité du recueil et l’accompagnement des équipes. Résultats attendus La capacité d’inclusion attendue de ce registre est de 300 à 400 cas par an. Il permettra ainsi de documenter de manière harmonisée les critères d’hospitalisation et les modalités de prise en charge des cas de leptospirose dans ces DROM. Il fournira des données indispensables pour évaluer les performances des tests diagnostiques (PCR sanguine, PCR urinaire, sérologie), identifier des facteurs pronostiques et caractériser l’épidémiologie microbienne (sérogroupes, génovars) ainsi que son impact sur les phénotypes cliniques. Il contribuera également à identifier des facteurs d’exposition communs ultramarins et spécifiques à chaque territoire, utile pour guider les mesures de prévention. A terme, une interface en lien avec la médecine de ville pourrait être envisagée afin de gagner en exhaustivité et représentativité. Discussion/Conclusion La mise en place du registre LEPTO-FROG représente une opportunité majeure d’harmoniser les pratiques et d’améliorer la prise en charge de la leptospirose dans les DROM. Les données produites permettront de réévaluer les stratégies diagnostiques en vie réelle, d’optimiser les parcours de soins et de développer des actions de prévention ciblées adaptés aux réalités locales. Ce registre s’inscrit donc pleinement dans les priorités de santé publique visant à améliorer la surveillance et la prise en charge d’une maladie fréquente et potentiellement grave.
In their article entitled “Morocco, a New Era of Robotic Surgery”, published in the Société Internationale d’Urologie Journal, El Anzaoui et al [...]
Background Fertility preservation is a core component of comprehensive cancer care, but its delivery can be uneven in geographically isolated settings with limited specialised resources. This study examined the organisation and reported activity of oncofertility services in Martinique, Guadeloupe and French Guiana, and compared territorial patterns with mainland France. Methods This multi-source descriptive study combined a structured narrative review of scientific publications, institutional reports and national and international guidelines published between 2007 and 2025 with a comparative analysis of aggregated cancer incidence and medical fertility preservation activity for 2018–2022. Procedure-to-incident cancer case ratios were calculated for corresponding age- and sex-specific groups. These ecological indicators were used only as descriptive proxies of activity and were not interpreted as coverage, uptake or cancer-specific procedure rates. Results The overall medical fertility preservation procedure-to-incident cancer case ratio was 17.3 procedures per 100 incident cancer cases in mainland France, compared with 6.2 in Guadeloupe, 1.8 in Martinique and 0.0 in French Guiana. Specialised fertility preservation services were concentrated in Guadeloupe. Martinique had limited private local capacity during the study period, whereas French Guiana relied on interterritorial referrals. The review identified geographical distance, logistical constraints, workforce shortages, variable professional awareness and fragmented referral pathways as the main organisational barriers. Conclusions Despite a common regulatory framework, oncofertility care delivery differed markedly across the French Departments of the Americas. Stronger interterritorial coordination, clearer referral pathways, professional training and local or satellite fertility preservation capabilities are needed to support more equitable and timely care in island and peripheral settings.
BACKGROUND:The diagnostic accuracy of prostate cancer has been improved by the use of multiparametric magnetic resonance imaging (MRI). However, the role of the Prostate Imaging-Reporting and Data System (PI-RADS) score in combination with MRI in predicting issues after local prostate cancer treatment remains unclear. The aim of this study was to evaluate the PI-RADS score as a predictive factor for biochemical recurrence or progression (BCR) of prostate cancer. METHODS:This retrospective monocentric study included 304 men who underwent targeted prostate biopsies plus standard biopsies after MRI between 2017 and 2020. All the included patients had a PI-RADS score of at least 3. Survival probabilities were estimated by the Kaplan-Meier method. The hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between individual characteristics and BCR or progression were estimated using the Cox proportional hazards regression model for univariate and multivariate analyses. All tests were two-sided, and P<0.05 was considered to indicate statistical significance. All analyses were performed using StatView software version 5.0 and MedCalc software version 17.5. RESULTS:In total, 283 patients were included in our study. The median age at biopsy was 67.8 years, and the median follow-up was 4.9 years. The median time to BCR or progression after active surveillance (AS) was 4.7 years. A total of 22.3% of the patients experienced biochemical recurrence. No risk factors for biochemical recurrence according to the MRI PI-RADS score were significantly identified by univariate or multivariate analyses. Biochemical-free survival was 87% for the PI-RADS 5 group, 90% for the PI-RADS 4 and 80% for the PI-RADS 3 group at 3 years. There were no significant differences among these three groups in terms of BCR-free survival (P=0.4). CONCLUSION:In the present study, MRI lesion description with PI-RADS or the usual risk group did not seem to be sufficient to predict biochemical recurrence after local prostate cancer treatment, especially in our particular population. Future studies could pair the PI-RADS with histologic data of the prostatic index lesion to predict recurrence. LEVEL OF EVIDENCE: 4: